MaxCyte, Oribiotech team on cell therapy manufacturing

MaxCyte (MXCT) and Oribiotech announced a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. This collaboration combines the MaxCyte ExPERT platform and Flow Electroporation technology with Ori’s cell therapy manufacturing platform, Iro. The collaboration will specifically evaluate how the IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte-engineered primary T cells compared to traditional post-electroporation cell expansion processes. Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation.